| Deerfield Care Center, Llc | |
| 575 Hospital Rd, New Richmond, Wisconsin 54017 | |
| (715) 243-3930 | |
| Name | Deerfield Care Center, Llc |
|---|---|
| Location | 575 Hospital Rd, New Richmond, Wisconsin |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 50 |
| Occupancy Rate | 86.8% |
| Medicare ID (CCN) | 525019 |
| Legal Business Name | Deerfield Care Center, Llc |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1427126739 |
| Organization Name | SIGNET HEALTH & REHAB |
| Address | 505 W 8th St, New Richmond, WI 54017 |
| Phone Number | 715-246-6851 |
News Archive
Roche announced today that the U.S. Food & Drug Administration (FDA) has approved the real-time PCR COBAS® TaqMan® HCV Test, v2.0. Clinical research organizations have depended on COBAS® TaqMan® technology to support hepatitis C pharmaceutical trials and development.
Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.
The National Cancer Institute has awarded $11.5 million to Fred Hutchinson Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. The goal of the endeavor is to positively impact breast cancer prevention, detection, treatment and care of women who have or are at risk for the disease.
The results of a large international cardiovascular trial will shed light on whether the addition of a new drug that prevents blood clotting, or thrombosis, can improve the treatment of the most serious form of heart attacks.
› Verified 6 days ago
| NPI Number | 1700057064 |
| Organization Name | DEERFIELD CARE CENTER, LLC |
| Address | 505 W 8th St, New Richmond, WI 54017 |
| Phone Number | 651-631-6120 |
News Archive
Roche announced today that the U.S. Food & Drug Administration (FDA) has approved the real-time PCR COBAS® TaqMan® HCV Test, v2.0. Clinical research organizations have depended on COBAS® TaqMan® technology to support hepatitis C pharmaceutical trials and development.
Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.
The National Cancer Institute has awarded $11.5 million to Fred Hutchinson Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. The goal of the endeavor is to positively impact breast cancer prevention, detection, treatment and care of women who have or are at risk for the disease.
The results of a large international cardiovascular trial will shed light on whether the addition of a new drug that prevents blood clotting, or thrombosis, can improve the treatment of the most serious form of heart attacks.
› Verified 6 days ago
| NPI Number | 1932118452 |
| Organization Name | TBN, LLC |
| Doing Business As | NEW RICHMOND MEADOWS |
| Address | 505 W 8th St, New Richmond, WI 54017 |
| Phone Number | 715-246-6851 |
News Archive
Roche announced today that the U.S. Food & Drug Administration (FDA) has approved the real-time PCR COBAS® TaqMan® HCV Test, v2.0. Clinical research organizations have depended on COBAS® TaqMan® technology to support hepatitis C pharmaceutical trials and development.
Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.
The National Cancer Institute has awarded $11.5 million to Fred Hutchinson Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. The goal of the endeavor is to positively impact breast cancer prevention, detection, treatment and care of women who have or are at risk for the disease.
The results of a large international cardiovascular trial will shed light on whether the addition of a new drug that prevents blood clotting, or thrombosis, can improve the treatment of the most serious form of heart attacks.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Roche announced today that the U.S. Food & Drug Administration (FDA) has approved the real-time PCR COBAS® TaqMan® HCV Test, v2.0. Clinical research organizations have depended on COBAS® TaqMan® technology to support hepatitis C pharmaceutical trials and development.
Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.
The National Cancer Institute has awarded $11.5 million to Fred Hutchinson Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. The goal of the endeavor is to positively impact breast cancer prevention, detection, treatment and care of women who have or are at risk for the disease.
The results of a large international cardiovascular trial will shed light on whether the addition of a new drug that prevents blood clotting, or thrombosis, can improve the treatment of the most serious form of heart attacks.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 9.48 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 4.42 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 72.31 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.58 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.32 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 3.38 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.55 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.05 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 13.64 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 83.46 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 30.72 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 11.11 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.15 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.91 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 78.62 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.77 | 82.93 |
News Archive
Roche announced today that the U.S. Food & Drug Administration (FDA) has approved the real-time PCR COBAS® TaqMan® HCV Test, v2.0. Clinical research organizations have depended on COBAS® TaqMan® technology to support hepatitis C pharmaceutical trials and development.
Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.
The National Cancer Institute has awarded $11.5 million to Fred Hutchinson Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. The goal of the endeavor is to positively impact breast cancer prevention, detection, treatment and care of women who have or are at risk for the disease.
The results of a large international cardiovascular trial will shed light on whether the addition of a new drug that prevents blood clotting, or thrombosis, can improve the treatment of the most serious form of heart attacks.
› Verified 6 days ago
Deerfield Care Center, Llc Location: 575 Hospital Rd, New Richmond, Wisconsin 54017 Phone: (715) 243-3930 | |
St Croix Health Center Location: 1445 N Fourth St, New Richmond, Wisconsin 54017 Phone: (715) 246-8211 |